Reducing Frailty for Older Cancer Survivors Using Supplements

NCT ID: NCT04553666 Phase: PHASE2 Status: COMPLETED Enrollment: 24 Completion: 2023-08-31

Conditions

Frailty, Inflammation

Interventions

Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)

Summary

The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer

Primary Outcome

Recruitment Feasibility: Rates of Consent

Source

ClinicalTrials.gov